Let us help you and us
Our Grants Portfolio
Objectives for Regenerative Medicine Innovation Projects Funding
To: Alleviate heavy burdens on patients and healthcare systems by developing smart nanoengineered affordable biomaterials for tissue self-healing and regeneration, and improve the well-being, health, quality of life and active ageing of populations
To: Boost industrial competitiveness and leadership of primarily Asia-based companies in personalised biointelligent materials responding to patients' clinical specificities
To: Further enhanced incorporation of digitalisation and Internet of Things for innovative and affordable biomaterials
The Tissue Engineering and Regenerative Medicine Program supports basic and translational research on employing bioengineering- and stem cell biology- based approaches for the reconstruction, repair, and regeneration of dental, oral, and craniofacial (DOC) tissues damaged because of disease or injury. The goal of this program is to advance engineering of biocompatible DOC tissue constructs and their functional integration into the host tissue microenvironment, and to support efforts aimed at healing and regeneration of endogenous host tissues.
Cardiovascular disease in the number one cause of death worldwide and it is the most common cause of death in the United States. This grant proposal is focused on novel regulators of cardiomyocyte proliferation and provides a platform for translational medicine in large animals during cardiac repair and regeneration. The aim of this grant proposal is to decipher the pathways and the mechanisms that govern adult cardiomyocyte proliferation and identify potential therapeutic targets to promote heart regeneration in vivo. This will serve as an important platform for the mechanistic as well as translational understanding of cardiac regeneration and will have a significant impact for the field of regenerative medicine. The studies in the injured pig heart are intended as a preclinical, translational initiative.
Spinal Cord Injury
Spinal cord injury often leads to loss of function below the injury, greatly reducing patient life expectancy and quality and, because the human nervous system lacks the ability to effectively self-repair, even partial recovery of function below the injury is rare. Mammals possess endogenous neuronal progenitor cells with stem cell-like properties that, under the right conditions, can be induced to proliferate and differentiate into new neurons. Yet, mammals have a very low capacity for neuronal regeneration when compared to fish and amphibians, which are capable of rapid regeneration of a wide variety of tissues and structures. This proposal will exploit the superior regenerative capacity and unique experimental toolbox available in the larval zebrafish to examine the roles of serotonergic signaling in promoting regeneration and functional recovery from spinal cord injuries.
Testing a therapeutic approach that genetically engineers each patient's own blood-forming stem cells to produce cancer-fighting immune cells called T cells.
The T cells used in the treatment will be modified to target NY-ESO-1, a protein that is highly produced by tumor cells of many cancers including melanoma and sarcoma. Ten to 20 percent of all cancers and 80 percent of synovial sarcomas have the NY-ESO-1 tumor marker.
Sarcomas account for one percent of all adult cancers and 15 percent of all pediatric cancers diagnosed annually in the United States. They generally fit into one of two categories: soft tissue sarcomas, which begin in fat, muscle, nerves, blood vessels and other connective tissues.